Literature DB >> 3783172

The distribution of multiple sclerosis in the United Kingdom.

R J Swingler, D Compston.   

Abstract

Parts of the United Kingdom have the highest incidence, prevalence and mortality rates for multiple sclerosis in the world. Although methods of ascertainment are not standardised, regional differences and changes with time are present for each of these statistics. Mortality has declined, whereas prevalence and hospital discharge rates have increased owing in part to the improved survival but also to better case ascertainment. The gradient in prevalence seen between Southern England (63/10(5)), Northern England and Northern Ireland (76-79/10(5)), Wales (c. 113/10(5)), North-East Scotland (155/10(5)) and the Orkneys (258/10(5)) can in part be attributed to varying methods of ascertainment but correlates with regional differences in the frequency of HLA-DR2 in normal individuals (21-50%). However no HLA-DR2 association is observed in parts of Scotland, where the prevalence is the highest in the United Kingdom, because HLA-DR2 and linked genes occur in up to 50% of the normal population from these areas. If the aetiology of multiple sclerosis is multifactorial the frequency of the disease will increase where susceptibility genes are common because the probability of concurrence of the remaining critical events is high; conversely when each aetiological agent is infrequent the chance of them all occurring in the same individual and therefore incidence of the disease are both lower. The fall in incidence observed in the Orkney Islands, possibly reflecting decline in an exogenous agent interacting with susceptibility factors, is consistent with this multifactorial hypothesis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3783172      PMCID: PMC1029043          DOI: 10.1136/jnnp.49.10.1115

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  18 in total

1.  MULTIPLE SCLEROSIS IN WINNIPEG, MANITOBA: METHODOLOGICAL CONSIDERATIONS OF EPIDEMIOLOGIC SURVEY. TEN YEAR FOLLOW-UP OF A COMMUNITY WIDE STUDY, AND POPULATION RE-SURVEY.

Authors:  A STAZIO; L T KURLAND; L G BELL; M G SAUNDERS; E ROGOT
Journal:  J Chronic Dis       Date:  1964-05

2.  Multiple sclerosis in the Orkneys.

Authors:  A Compston
Journal:  Lancet       Date:  1981-07-11       Impact factor: 79.321

3.  Genetic analysis of multiple sclerosis in Orkney.

Authors:  D F Roberts; M J Roberts; D C Poskanzer
Journal:  J Epidemiol Community Health       Date:  1979-12       Impact factor: 3.710

4.  B-lymphocyte alloantigens associated with multiple sclerosis.

Authors:  D A Compston; J R Batchelor; W I McDonald
Journal:  Lancet       Date:  1976-12-11       Impact factor: 79.321

5.  A further prevalence study of multiple sclerosis in north-east Scotland.

Authors:  D I Shepherd; A W Downie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-04       Impact factor: 10.154

6.  Prevalence of multiple sclerosis in West Yorkshire.

Authors:  M McCoubrie; D Shuttleworth
Journal:  Br Med J       Date:  1978-08-19

7.  Prevalence of multiple sclerosis in north-east Scotland.

Authors:  D I Shepherd; A W Downie
Journal:  Br Med J       Date:  1978-07-29

8.  Forms of benign multiple sclerosis. Report of two "clinically silent" cases discovered at autopsy.

Authors:  R P Mackay; A Hirano
Journal:  Arch Neurol       Date:  1967-12

9.  Multiple sclerosis in the Orkney and Shetland Islands. I: Epidemiology, clinical factors, and methodology.

Authors:  D C Poskanzer; L B Prenney; J L Sheridan; J Y Kondy
Journal:  J Epidemiol Community Health       Date:  1980-12       Impact factor: 3.710

10.  Multiple sclerosis in the Orkney and Shetland Islands. III: Histocompatibility determinants.

Authors:  D C Poskanzer; P I Terasaki; L B Prenney; J L Sheridan; M S Park
Journal:  J Epidemiol Community Health       Date:  1980-12       Impact factor: 3.710

View more
  27 in total

Review 1.  Multiple sclerosis, vitamin D, and HLA-DRB1*15.

Authors:  Lahiru Handunnetthi; Sreeram V Ramagopalan; George C Ebers
Journal:  Neurology       Date:  2010-06-08       Impact factor: 9.910

2.  Multiple sclerosis in Australia and New Zealand: are the determinants genetic or environmental?

Authors:  D H Miller; S R Hammond; J G McLeod; G Purdie; D C Skegg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-10       Impact factor: 10.154

3.  Risk factors for multiple sclerosis: race or place?

Authors:  A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-10       Impact factor: 10.154

4.  The prevalence of multiple sclerosis in the Southampton and South West Hampshire Health Authority.

Authors:  M H Roberts; J P Martin; D L McLellan; S A McIntosh-Michaelis; A J Spackman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

5.  Mortality rates from multiple sclerosis: geographical and temporal variations revisited.

Authors:  E S Williams; D R Jones; R O McKeran
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-02       Impact factor: 10.154

6.  Multiple sclerosis in south Cambridgeshire: incidence and prevalence based on a district register.

Authors:  N Robertson; J Deans; M Fraser; D A Compston
Journal:  J Epidemiol Community Health       Date:  1996-06       Impact factor: 3.710

7.  Multiple sclerosis: nature or nurture?

Authors:  D C Skegg
Journal:  BMJ       Date:  1991-02-02

8.  The prevalence of multiple sclerosis in the Leeds Health Authority.

Authors:  H L Ford; E Gerry; C M Airey; A Vail; M H Johnson; D R Williams
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

9.  Class II HLA antigens in multiple sclerosis.

Authors:  D H Miller; R W Hornabrook; J Dagger; R Fong
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-05       Impact factor: 10.154

10.  Clinical, CSF, and MRI findings in Devic's neuromyelitis optica.

Authors:  J I O'Riordan; H L Gallagher; A J Thompson; R S Howard; D P Kingsley; E J Thompson; W I McDonald; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-04       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.